Epstein-Barr nuclear antigen 1-derived peptide–Human leukocyte antigen complex (EBNA1-HLA complex)

The Epstein-Barr nuclear antigen 1 (EBNA1)-derived peptide–Human leukocyte antigen (HLA) complex is a critical immunological target for treating Epstein-Barr virus (EBV)-associated diseases. EBNA1 is a DNA-binding protein required for the replication and persistence of the EBV genome and is uniquely expressed in all EBV-related malignancies, including Nasopharyngeal carcinoma and various lymphomas (UniProt: P03211). Peptides derived from EBNA1 are processed and presented on the cell surface by HLA Class I and Class II molecules, serving as specific markers for T-cell recognition. Because EBNA1 is a foreign viral protein, these peptide-MHC (pMHC) complexes provide a highly specific target for immunotherapies such as TCR-engineered T cells and TCR-mimetic antibodies, which aim to eliminate infected cells while minimizing damage to healthy tissues. However, therapeutic development must account for the protein's Gly-Ala repeat domain, which can inhibit proteasomal degradation and Class I presentation (Taylor et al., J Exp Med 2004). Additionally, research into Multiple Sclerosis has highlighted the risk of molecular mimicry, where immune responses against EBNA1-HLA complexes may cross-react with host proteins like GlialCAM (Lanz et al., Nature 2022).

Other names

EBNA1-pMHC complexEBNA1 peptide-MHC complexEBNA1-HLA-A*02:01 complexEBNA1-HLA-DR complexEBNA1-derived peptide–HLA class I/II complexes

T-cell receptor (TCR) mediated cytotoxicity, Antibody-dependent cellular cytotoxicity (ADCC) via TCR-mimetics, Vaccine-induced T-cell priming